bims-madeba Biomed News
on Mal de débarquement syndrome
Issue of 2026–01–18
one paper selected by
Jun Maruta, Mount Sinai Health System



  1. Zh Nevrol Psikhiatr Im S S Korsakova. 2025 ;125(12): 200-207
       OBJECTIVE: To assess the prevalence and clinical features of the syndrome (fr.: Mal de Débarquement Syndrome, MdDS) in patients with vertigo, comorbidity with other vestibular and neurological disorders.
    MATERIAL AND METHODS: 2738 patients (77.7% women) aged 18 to 70 years who were observed in the Department of Otolaryngology of the Clinical Hospital named after. Peter the Great North-Western State Medical University named after I.I. Mechnikov in the period from 2023 to 2024. The examination included neuroimaging, electroencephalography, duplex scanning of the vessels of the head and neck, neurological and otoneurological examination.
    RESULTS: The most common form is benign paroxysmal positional vertigo (BPPV), the second most common is vestibular paroxysmia, and the third most common is Ménière's disease. In many patients, the occurrence of vertigo was triggered by a combination of several diseases. Every fourth patient had a complication in the form of Persistent Postural Perceptual Vertigo (PPPV). PPPV was a complication of previous episodes of peripheral and central vertigo, but it most often developed in patients with MdDS. MdDS is associated with vestibular paroxysmia (38.9%), DPPG (11.1%), and vestibular migraine (5.6%). A clinical observation of a patient with MdDS is presented.
    CONCLUSION: MdDS is a rare condition that requires the exclusion of other forms of vertigo. The use of a set of diagnostic tests allows for an accurate diagnosis and the selection of the correct treatment strategy.
    Keywords:  Cytoflavin; Mal de Débarquement Syndrome; balance disorders; dizziness; vestibular migraine
    DOI:  https://doi.org/10.17116/jnevro2025125121200